SKYEPHARMA ANNOUNCES FORADIL(R) CERTIHALER(TM) LAUNCHED IN GERMANY

SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today that its partner Novartis Pharma AG (Novartis) has launched FORADIL(R) CERTIHALER(TM) (formoterol fumarate inhalation powder) on the German market for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The German pharmaceutical regulatory authority approved FORADIL(R) CERTIHALER(TM) in June. FORADIL(R) CERTIHALER(TM) is a trademark of Novartis.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-07-2005/0004101498&EDATE=)